Long-term data support tolerability goal of new schizophrenia med

4 January 2024
alkermesbig

Dublin-headquartered Alkermes (Nasdaq: ALKS) has announced new long-term data from a Phase III trial of Lybalvi (olanzapine/samidorphan).

The therapy is  approved for the treatment of schizophrenia and bipolar I disorder in the USA, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes.

The topline data show that 35.9% of participants completed the four-year treatment period, and safety results were consistent with previous studies.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical